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INTRODUCTION
Ovarian tumors grow in combined cystic and solid formations. 
There is no reliable diagnostic test or imaging technique avai  la  ble 
to distinguish benign from malignant cysts [1]. The decision to 
operate is based on clinical findings, transvaginal sonography, 
com  puted tomography and/or magnetic resonance imag-
ing, and cancer antigen 125 (CA-125) levels. Approximately 7 
to 10 benign lesions are operated on for each case of ovarian 
cancer found [2]. Consequently, several patients undergo ex-
tensive surgical staging, including oophorectomy, without an 
assured diagnosis of a malignant tumor, resulting in increased 
morbidity. Thus, there would be both medical and socio-
economic benefits if we could preoperatively identify patients 
with benign cysts and safely be able to recommend conserva-
tive laparoscopic staging operations [3].
The tumor marker CA-125 is used to predict the presence 
of malignancy in patients with a pelvic mass [4]. CA-125 is 
elevated (>35 U/mL) in 80% of cases of advanced cancer, but 
in fewer than 50% of cases in early stages. Moreover, CA-125 
is often elevated in different benign gynecologic and non-
gynecologic conditions and in premenopausal women [5]. 
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Objective: Women presenting with a large or complex ovarian cyst are referred to extensive surgical staging to ensure the 
correct diagnosis and treatment of a possible epithelial ovarian cancer. We hypothesized that measurement of the biomarkers 
HE4 and CA-125 preoperatively would improve the assignment of these patients to the correct level of care.
Methods: Patients diagnosed with a cystic ovarian mass and scheduled for an operation at our center of excellence for ovarian 
cancer surgery from 2001 to 2010 were prospectively included (n=394) and plasma was collected consecutively. Cut-off for HE4 
was calculated at 75% specificity (85 pM and 71.8 pM for post and premenopausal women). For CA-125, 35 U/mL cut-off was 
used. The study population included women with malignant (n=114), borderline (n=45), and benign (n=215) ovarian tumors.
Results: Receiver operator characteristic (ROC) area under the curve (AUC) in the benign versus malignant cohorts was 86.8% 
for CA-125 and 84.4% for HE4. Negative predictive value was 91.7% when at least one of the biomarkers was positive, with only 
early stage epithelial ovarian cancer showing false negative results. Sensitivity at set specificity (75%) was 87% for risk of ovarian 
malignancy algorithm (ROMA) in the postmenopausal cohort (cut-off point, 26.0%) and 81% in the premenopausal cohort (cut-
off point, 17.3%). ROC AUC in the benign versus stage I epithelial ovarian cancer was only 72% for HE4 and 76% for CA-125.
Conclusion: In our study, population HE4 did not outperform CA-125. Based on our data a prospective trial with patients already 
diagnosed with an ovarian cyst may be conducted.
Keywords: CA-125, Human epididymis protein 4, Ovarian cancer, Risk of ovarian malignancy algorithm
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Human epididymis protein 4 (HE4) is a prominent new can-
didate for the detection of ovarian cancer [6,7]. The marker 
was discovered in RNA expression arrays comparing normal 
epithelial cells and malignant tumors [8,9]. Hellstrom and col-
leagues [10] constructed HE4 antibodies and reported that 
in a rather small study population HE4 and CA-125 in serum 
samples detected ovarian cancer equally, but HE4 had a bet-
ter capacity to distinguish healthy women and women with 
benign disease from those with malignant tumors. The find-
ings indicated that HE4 used in combination with CA-125 
might be a promising tool for the detection of ovarian cancer. 
Moore and colleagues [11] have created an algorithm for risk 
scoring called the risk of ovarian malignancy algorithm (ROMA) 
based on menopausal status and preoperative measurement 
of the dual markers. ROMA classifies women with ovarian cyst 
or pelvic mass scheduled to undergo surgery into low- and 
high-risk groups. Today, the question still remains whether 
HE4, ROMA, or both add sufficient information to CA-125 to 
be implemented in clinical practice [12,13]. 
It is evident that an early diagnosis is the most important fac-
tor for substantial improvement in the survival rate of patients 
with ovarian cancer, as shown by 5-year survival rates of over 
80% for women in early stages to under 30% for those in stag-
es III-IV [14]. The first published studies indicated that HE4 has 
higher sensitivity in identifying early stage disease than does 
CA-125 [7,15]. Conversely, later studies have shown CA-125 to 
be the best marker for detecting early stage disease [6,16].
We first hypothesized that known ovarian cysts in a study 
population might be better classified with HE4 alone or in 
combination with CA-125 than with CA-125 alone. Second, 
we intended to estimate an optimal cut-off value for HE4 in 
our study population [11,17]. Third, we intended to indepen-
dently validate ROMA. We prospectively collected blood and 
tumor tissue from patients presenting with a suspicious ovar-
ian cystic pelvic mass from 2001 to 2010. The patients had al-
ready been assigned to operation at our center of excellence 
for ovarian cancer surgery. 
MATERIALS AND METHODS
1. Study population
The study population (n=374) comprised of women with 
benign ovarian tumors (n=215), borderline type tumors 
(n=45), and epithelial ovarian cancer (EOC; n=114) (Table 1). 
Menopause status, defined as one year of amenorrhea, was 
checked for women between 47 and 56 years of age. Patients 
<47 years old were considered premenopausal, and women 
>56 years were considered postmenopausal. The local eth-
ics committee at Gothenburg University approved the study 
protocol and samples were collected consecutively from all 
patients presenting with a suspected malignant ovarian cystic 
mass who signed a written informed consent. After surgery, 
tumors were examined by an experienced pathologist for 
diagnosis, histology, and grade and staged (I-IV) according to 
International Federation of Gynaecology and Obstetrics (FIGO) 
standards (Table 2).
Table 1. Patient and tumor histology characteristics
Benign Borderline Malignant
Pre­
menopausal
Post­
menopausal
All  Pre­
menopausal
Post­
menopausal
All  Pre­
menopausal
Post­
menopausal
All 
Age (yr) 41 (16­52) 66 (47­88) 60 (16­88) 40 (18­52) 65 (47­85) 50 (18­85) 44 (28­56) 65 (48­88) 61 (28­56)
Total 50 (23.3) 165 (76.7) 215 27 (60) 18 (40) 45 21 (18.4) 93 (81.6) 114
Histology
Simple 11 36 47 (22)
Endometrioma   5   6 11 (5)
Hemorrhagic   2   2 4 (2)
Stromal   2 11 13 (6)   0   1 1 (2)
Teratoma   8   4 12 (6)   1   0 1 (2)   0   1 1 (1)
Serous   7 69 76 (35) 17   7 24 (53) 10 62 72 (63)
Mucinous 15 37 52 (24)   8 10 18 (40)   4   7 11 (10)
Endometrioid   1   0 1 (2)   6 11 17 (15)
Clear cell   0   7 7 (6)
Undifferentiated   1   5 6 (5)
Values are presented as mean (range) or number (%).Karolina Partheen, et al.
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2. Inclusion and exclusion criteria
Patients were prospectively included when admitted to opera-
tion for a clinically suspicious ovarian cystic mass at the section 
for gynecologic oncology surgery, Sahlgrenska University Hos-
pital, Gothenburg, Sweden from 2001 to 2010. Patients were 
selected for operation at this specialized unit when diagnosed 
with a suspected malignant ovarian cystic mass. Generally, the 
criteria used for this selection were pre- or postmenopausal 
status, prior family or personal history of ovarian or breast can-
cer, and size, complexity at transvaginal ultrasound (double or 
multiple cysts, thick walls, excrescences), and fixed or bilateral 
nature of the tumors. Patients with a solid pelvic tumor were 
not invited to participate. Patients who did not want to be 
in  cluded were excluded. The patient was excluded if final his-
tology showed the origin of the tumor was not ovarian. 
3. Sample collection, processing, and storage 
Blood samples were collected after anesthesia but before 
surgery. Six milliliters of blood were collected in citrated vacu-
tainers using standardized procedures and stored at 4
oC with-
in 15-30 minutes. Plasma was collected after centrifugation, 
directly aliquoted into Eppendorf tubes, frozen, and stored at 
-80
oC within 30-60 minutes after withdrawal. Handling and 
processing were standardized for all patients included in the 
investigation. All analyses were performed on plasma.
4. HE4 and CA-125 analyses
The analyses were performed on plasma from patients di-
agnosed with a suspicious ovarian cystic mass, while serum is 
the ordinary analytic fluid to be used according to the manu-
facturer’s instructions (Fujirebio Diagnostics, Goteborg, Swe-
den). Fujirebio Diagnostics performed a correlation study of 
plasma and serum HE4 levels prior to our analysis. Plasma and 
serum were drawn simultaneously from 44 women. Levels of 
HE4 matched with an acceptable correlation (R2=0.90). 
HE4 plasma concentrations were determined using the HE4 
EIA assay (Fujirebio Diagnostics) and plasma CA-125 levels were 
measured using Architect CA-125 II (Abbott Diagnostics, Ab-
bott Park, IL, USA) at Fujirebio Diagnostics. The analytical runs 
of the biomarkers fulfilled the laboratory QC criteria for each 
analysis based on QC-samples within acceptance limits as well 
as dose response and reproducibility within predetermined 
limits. The laboratory technician performing the assays was 
blinded to both clinical diagnoses and individual pathology 
results and the pathologist was blinded to laboratory values. 
5. Statistical analyses
Currently, there is no recommended cut-off value for HE4. 
According to the protocol from the manufacturer, 23 of 347 
women (6.6%) with benign gynecological disease have HE4 
>150 pM. Among apparently healthy females a cut-off value 
of 70 pM has been suggested [11], however, the value may 
vary depending upon the study population. Our analysis in-
cludes only patients already diagnosed with a suspicious cys-
tic ovarian mass, so the cut-off value for this group had to be 
determined for HE4 and ROMA. In line with Moore et al. [11], 
who presented a comparable study population, specificity 
was fixed at 75% and the cut-off value in our material for that 
outcome was calculated for HE4 and ROMA. ROMA was esti-
mated as previously described. If the sensitivity then exceeded 
80%, at least 80% of the patients with malignant cystic pelvic 
masses would be operated on at the specialist unit for gyne-
cologic oncology surgery. The threshold for positive diagnosis 
by CA-125 was set at 35 U/mL, which is routinely used in our 
clinic. Specificity and sensitivity for CA-125 were calculated us-
ing >35 U/mL as the cut-off point. 
Statistical differences in protein levels between groups were 
evaluated using the Mann-Whitney U-test. Sensitivity, speci-
ficity, positive predictive value (PPV), and negative predictive 
value (NPV) were calculated for each marker and for ROMA. 
The protein levels were subjected to logistic regression analy-
sis, the predictive probabilities for each model were used to 
construct receiver operating characteristic (ROC) curves, and 
area under the curve (AUC) values were calculated. For all sta-
tistical comparisons a value of p<0.05 was considered signifi-
cant. Statistical analyses were performed in SPSS ver. 17.0 (SPSS 
Inc., Chicago, IL, USA).
RESULTS
1. Patient material
We enrolled 394 patients with a suspicious cystic ovarian 
Table 2. Stage and grade by menopausal status for malignant samples
 
 
Premenopausal
(n=21)
Postmenopausal
(n=93)
Total
(n=114) 
Stage
I 11 36 47 (41.2)
II 3 7 10 (8.8)
III 7 14 51 (44.7)
IV 0 6 6 (5.3)
Grade
1 8 28 36 (31.6)
2 8 18 26 (22.8)
3 5 47 52 (45.6)
Values are presented as number (%).HE4 and CA-125 in ovarian cancer diagnoses
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mass and excluded 20 because of non-ovarian histology. Of 
the 374 patients eligible for analysis, 57.5% had benign tu-
mors, 12.0% had borderline tumors, and 30.5% had EOC (Table 
1). Mean age in relation to menopausal status was equally dis-
tributed within the three cohorts, while overall mean age for 
the borderline cohort was 10 years younger. Serous histology 
was the most common diagnosis among the three cohorts. 
Mucinous histology was relatively higher in the benign and 
borderline cohorts than in the group with malignant tumors. 
In patients with EOC, 57 (50%) were diagnosed with early 
stage (I-II) and 57 (50%) with late stage (III-IV) disease (Table 2). 
2. HE4 and CA-125 levels significantly separate the benign-
tumor from the malignant-tumor cohort 
Analysis of tumor-marker levels was performed blinded and 
the cohort samples were mixed. A visual description of HE4 
and CA-125 correlation within the 3 cohorts is presented in 
Fig. 1. Median HE4 plasma level for all benign-tumor patients 
was 66 pM (Table 3). Levels of HE4 significantly (p<0.001) dis-
tinguished the benign-tumor cohort from those with stage I 
EOC and those with any EOC, but not from those with border-
line type tumors (Table 3). Significance was also reached, ex-
cept for borderline type tumors in the premenopausal group, 
for distinguishing the cohorts into pre- and postmenopausal 
groups. Both biomarkers and ROMA demonstrated signifi-
cance with low stringency (p<0.05) for benign versus stage I 
tumors in the premenopausal group. The median plasma level 
for CA-125 for all patients with benign tumors was 16 U/mL 
(range, 2 to 4,632 U/mL) (Table 3). Levels of CA-125 were sig-
nificantly (p<0.001) different between the cohort with benign 
tumors and those with borderline tumors, stage I EOC, and all 
EOC (Table 3). Significance was also reached in distinguishing 
the cohorts into pre- and postmenopausal groups. The dual 
marker algorithm, ROMA, implemented by Moore et al. [11] 
was subsequently calculated for the study population, again 
clearly separating (p<0.001) the benign-tumor from the ma-
lignant-tumor cohort and the benign from early stage I EOC 
(p<0.05) for both pre- and postmenopausal women (Table 3). 
The diagnostic accuracy of CA-125 and HE4 alone, in com-
bination, and for ROMA was assessed by estimating ROC and 
AUC for patients with benign versus malignant tumors (Fig. 
2). The highest ROC AUC was calculated for ROMA and CA-
125 (87%), followed by the combination of CA-125 and HE4 
(85%), and HE4 alone (84%) (Fig. 2, Table 4). Specificity was set 
to 75% for HE4, which we considered relevant for our selected 
material of suspicious cystic ovarian mass. At this level, to dis-
tinguish between the benign-tumor and the malignant-tumor 
Fig. 1. Correlation between HE4 and CA­125. Logarithmic scales are used, 
and the dotted lines show cut­off values. HE4, 85 pM; CA­125, 35 U/mL.
Table 3. Tumor marker levels and risk of ovarian malignancy algorithm (ROMA) among patients with benign, borderline type, and malignant 
samples
Benign Borderline Stage I malignant All malignant
HE4 (pM) 65.7 71.0 102.5
† 190.0
†
Premenopausal 56.9 (30.6­469.0) 68.7   (35.8­120.8) 79.7* (41.2­1,729.9) 160.8
† (41.2­1,729.9)
Postmenopausal 68.6 (34.2­631.4) 85.2* (57.6­277.3) 105.5
† (38.7­1,111.1) 210.1
† (38.7­7,931.9)
CA­125 (U/mL) 16.2 51.8
† 49.7
† 204.2
†
Premenopausal 22.9 (6.3­121.0) 52.6
† (9.7­652.8) 49.7* (19.8­2,377.5) 87.6
† (19.8­4,232.7)
Postmenopausal 14.3 (2.3­4,631.6) 49.8
† (8.4­599.9) 54.3
† (6.2­2,932) 264.7
† (6.2­14,880.2)
ROMA (%) 13.0 20.9* 42.0
† 80.7
†
Premenopausal 10.1 (2.4­94.1) 14.4* (3.6­44.6) 20* (4.9­99.8) 60.0
† (4.9­99.8)
Postmenopausal 13.9 (4.4­96.7) 34.2
† (9.5­83.7) 45
† (5.0­98.4) 85.9
† (5.0­100.0)
Values are presented as median (range). *p< 0.05. 
†p< 0.001.Karolina Partheen, et al.
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cohorts, the estimated cut-off for HE4 was 85 pM. When using 
this cut-off sensitivity for HE4, CA-125 (specificity 80% at cut-
off 35 U/mL) was 78% and 82% respectively. The best sensitiv-
ity (89%) and negative predictive value (92%) were achieved 
when at least one of the two biomarkers was positive at the 
set cut-off points (specificity 66%). In addition, we estimated 
the most common cut-off for HE4 used in previous investiga-
tions at 70 pM [11]. At this cut-off the sensitivity was 88% and 
the specificity 57% in our material. On examining the group 
of patients with malignant tumors who had negative results 
for one or both of the biomarkers (false negatives), we found 
that most were in FIGO stage I (CA-125, 18 of 21 false nega-
tives; HE4, 19 of 25 false negatives; HE4+CA-125, 12 of 13 false 
negatives). In the last group (HE4+CA-125) 100% of the false 
negatives were in stage I (n=12) or stage II (n=1). False posi-
tives in the benign cohort were evenly distributed between 
the major histological subgroups for each biomarker, except 
for CA-125 in endometrioma, which had a much higher rate 
of false positives (45%).
The study population was subsequently divided into a pre- 
and a postmenopausal group. The ROC AUC values for the 
premenopausal cohort were similar for HE4 (82%), CA-125 
(85%), and ROMA (83%) (Table 4). The cut-off value for HE4 
Fig. 2. Receiver operating characteristic curves of benign vs. malignant 
cases. ROMA, risk of ovarian malignancy algorithm.
Table 4. ROC AUC, sensitivity, specificity for set cut­off points, PPV and NPV of HE4, CA­125, and ROMA comparing benign and different 
combinations of malignant samples
  ROC AUC (95% CI) Specificity Sensitivity PPV NPV
Malignant (n=114)
HE4 (85 pM) 84.4 (79.5­89.2) 75 78.1 62.2 86.6
CA­125 (35 U/mL) 86.8 (82.3­91.4) 80 81.6 68.9 89.2
HE4 (85 pM)+CA­125 (35 U/mL) 84.8 (80.1­89.6) 66 88.6 58.0 91.7
Malignant premenopausal (n=21)
HE4 (71.8 pM) 82.3 (70.4­94.2) 75 80.9 56.7 90.2
CA­125 (35 U/mL) 84.6 (75.1­94.2) 75 76.2 55.2 88.1
ROMA (17.3%) 83.1 (71.6­94.7) 75 81.0 60.7 90.7
Malignant postmenopausal (n=93)
HE4 (85 pM) 84.8 (79.5­90.1) 75 80.6 61.0 90.7
CA­125 (35 U/mL) 87.0 (81.8­92.1) 83 82.8 72.6 89.5
ROMA (26%) 88.7 (84.2­93.2) 75 87.1 62.8 90.7
Stage I (n=47)
HE4 (85 pM) 72.2 (63.4­81.1) 75 59.6 34.1 89.4
CA­125 (35 U/mL) 76.3 (68.1­84.4) 80 61.7 40.8 90.6
Borderline (n=45)
HE4 (85 pM) 58.2 (49.6­66.8) 75 35.6 22.9 84.7
CA­125 (35 U/mL) 78.8 (71.8­85.7) 80 62.2 40.0 91.0
Values are presented as % (95% Cl). 
ROC, receiver operator characteristic; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; ROMA, risk of 
ovarian malignancy algorithm.HE4 and CA-125 in ovarian cancer diagnoses
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was separately calculated in the premenopausal group as 71.8 
pM and for ROMA as 17.3% at 75% specificity. The sensitivity 
among premenopausal women was higher for ROMA and 
HE4 (both 81%) than for CA-125 (76%). The cut-off point for 
ROMA in the postmenopausal group at 75% specificity was 
estimated as 26.0%. The sensitivity among postmenopausal 
women was very good for ROMA (87.1%) and diagnostic ac-
curacy described by ROC AUC values were 85% for HE4, 87% 
for CA-125, and 89% for ROMA. Both biomarkers and ROMA 
diagnosed malignant disease more correctly in postmeno-
pausal women than in premenopausal women. 
The performance of CA-125 was the best of the markers in 
distinguishing between women with stage I EOC versus be-
nign tumors, with an ROC AUC of 76% compared with 72% for 
HE4 (Table 4). Both sensitivity and specificity was higher for 
CA-125 in stage I EOC at the set cut-off points. Due to small 
sample size, stage I EOC was not divided into a pre- and post-
menopausal group in the analysis, which could have affected 
the individual biomarkers performance. Calculation of ROC 
AUC and sensitivity in the groups with benign versus border-
line type tumors did not add any useful clinical information 
(Table 4). Median levels of mucinous EOC were low in both 
the borderline and the stage I tumor groups, leading to sev-
eral false negatives. In fact, the overall majority of false nega-
tives were found in these two subgroups, strongly affecting 
the ROC AUC outcome.
DISCUSSION
We used consecutively collected blood samples from 374 
patients scheduled for surgery for a suspicious cystic ovarian 
or pelvic mass and analyzed the levels of HE4 and CA-125. We 
found that HE4 did not perform better than CA-125 results in 
the total material, but may be more useful in premenopausal 
women. Negative predictive value was high (92%) if CA-125, 
HE4, or both were elevated, and all false negatives were found 
in early stage EOC. This finding suggests that HE4 adds infor-
mation in the preoperative workup. 
Women presenting with a suspicious ovarian cyst or cystic 
pelvic mass are presently commonly exposed to open lapa-
rotomy and an extensive staging operation. A patient with 
this diagnosis should always be operated on at a unit where 
the gynecologic surgeons are trained in optimal debulking 
surgery [18]. On the other hand, approximately 7 to 10 benign 
cysts are removed for each single discovery of ovarian cancer 
[2]. The lack of preoperative screening modalities to predict 
diagnostic outcome increases unnecessary extensive abdomi-
nal ovarian staging operations. The risk of malignity index 
(RMI), an algorithm based on CA-125, menopausal status, and 
transvaginal sonography, was the first to be used for referral 
of ovarian cancer patients [19]. Another algorithm, ROMA, 
based on HE4, CA-125, and menopausal status, was shown to 
stratify patients into high- and low-risk groups, enabling more 
accurate triage of patients to centers of excellence for ovarian 
cancer than RMI [20], while McDonald et al. [21] concluded 
that patients with solid or complex ovarian tumors and el-
evated CA-125 were those at high risk of ovarian malignancy. 
The results from our investigation suggest that adding mea-
surements of HE4 to CA-125 in the preoperative evaluation 
of a suspicious ovarian cyst or cystic pelvic mass may help to 
choose the correct type and setting for the operation. If we 
had evaluated HE4 and CA-125 in addition to TVS and CT pre-
operatively, the majority of the patients in our study popula-
tion could have had conservative laparoscopic staging, with-
out the risk of an incorrect diagnosis [3] since every one of the 
13 false negatives were in the early stage. With the incorpora-
tion of this measure preoperatively, not only will the patient 
have fewer preoperative complications and less co-morbidity 
due to unnecessary abdominal procedures, but she will also 
have a shorter stay at the hospital, be back to her ordinary life 
more quickly, and be left with one intact ovary. 
Several groups have investigated HE4 in a possible screen-
ing setting and report good ROC AUC separating women with 
either early or late stage epithelial ovarian cancer from healthy 
controls [10,16,22,23]. HE4 is a biomarker that increases 
progressively with disease and is markedly lower in healthy 
women than in women with benign ovarian cysts [12]. This 
fact makes comparisons between the above-mentioned stud-
ies, which include patients without disease of the ovaries, and 
studies like ours and others [6,24], which compare prospective 
data from known ovarian masses less relevant. Very promising 
results that separate benign from malignant disease using HE4 
alone have presented ROC AUC of 95% [25] and 91% [7], while 
we and others reached an ROC AUC of 84%, 84% [6], and 86% 
[24]. Different cut-off points, more postmenopausal women 
in the benign cystic cohort, and the fact that we analyzed 
plasma instead of serum could have influenced our results. As 
in several other studies, CA-125 performed better than HE4 in 
our estimation, not only in the whole group but also when we 
divided the cohorts into benign versus borderline and stage I 
EOC. 
The sample characteristics in our investigation differ from 
the normal distribution one could expect because the pa-
tients were already qualified for operation at our centre of 
excellence for ovarian cancer surgery. Compared to a popu-
lation-based incidence of operated ovarian cysts our cohort 
included fewer benign samples (58%), more early stage EOC Karolina Partheen, et al.
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(50%), and more postmenopausal women (74%). The young, 
fertile women with simple cysts considered to have a low risk 
of malignancy were operated on at the benign gynecology 
unit and were never part of the investigation. It is important 
to be aware that the composition of study populations varies 
greatly between published studies and very few present data 
from a normal clinical setting without exclusions. Relatively 
high or low numbers of women with endometrioma or mu-
cinous tumors also affect the overall results for both biomark-
ers in analyses [26,27]. A large older population in the benign 
cohort, as in ours, will affect analyses because HE4 increases 
every two years in healthy postmenopausal women [28] and 
CA-125 decreases after menopause [26,29]. Both Moore et 
al.  [11] and Van Gorp et al. [24] had more premenopausal 
women (57% and 47% compared to our 26%) in the benign 
group than we did. Another difference is the large proportion 
of early stage EOC in our study. Aggressive EOC with large 
numbers of small peritoneal metastases and ascites (stage III-
IV) seldom present themselves with cystic formations. These 
stage III-IV tumors were excluded according to the study cri-
teria and could account for a lower proportion of late stage 
tumors than expected.
In healthy premenopausal women CA-125 is more often 
elevated than HE4 in different benign gynecologic conditions 
[5,11,23]. This is also true for our data, suggesting that HE4 is a 
good complement to distinguish CA-125 false positives from 
true positives, especially in fertile women. A previous investi-
gation of serum from healthy women and women with ovar-
ian cancer showed that CA-125 is a better marker than HE4 for 
women age 50 and over, and that HE4 had better specificity 
among women under the age of 50 [23]. Further, an investiga-
tion comparing benign and malignant tumors showed that 
HE4 had greater sensitivity than CA-125 among premeno-
pausal women, and that CA-125 and HE4 perform at the same 
level among postmenopausal women [7]. We can confirm 
that HE4 yields higher sensitivity and is a more stable marker 
in premenopausal women at a set specificity than CA-125. For 
postmenopausal women CA-125 (with a cut-off of 35 U/mL) 
yielded higher specificity than for premenopausal women 
(83% vs. 75%).
The cut-off value for HE4 at 75% specificity in our analysis 
was 85 pM but mean HE4 levels were lower in the premeno-
pausal women. Estimated cut-off in this group was 71.8 pM, 
which accords with the cut-off of 70 pM used in other stud-
ies [11,24,27]. Most algorithms for the referral of patients are 
based on an evaluation of TVS alone or in combination with 
biomarkers and menopause status [1,19,21]. Indeed TVS was 
performed on all patients in our cohort, but not in a stan-
dardized way. Instead, we calculated ROMA in our cohort. 
Diagnostic accuracy of ROMA described by ROC AUC was 
estimated at 88.7% (postmenopaus) and 83.1% (premeno-
paus), which is well in line with other published data. If both 
markers are measured in the future, the clinician may look at 
the independent values for the two markers (highest negative 
predictive value but lower specificity) or be calculating ROMA. 
HE4 and CA-125 in each patient might also need to be evalu-
ated according to other factors such as chronic or intermittent 
disease, BMI, and smoking [28]. In our benign group, the three 
highest values of HE4 belonged to two patients with chronic 
kidney failure, a disease known to have increased HE4 values, 
and one patient with breast cancer, suggesting that patient 
history should be accounted for more strictly when the results 
of new biomarkers are being evaluated.
CA-125 is known to have low sensitivity and specificity in 
women with early stage cancer. Previous findings of the per-
formance of HE4 and CA-125 in early stage tumors are contra-
dictory, favoring both CA-125 and HE4 as the best marker to 
detect early disease [6,7,10]. We found that the ROC AUC and 
sensitivity were slightly higher for CA-125 than for HE4. The 
number of early stage tumors in the studies range from 7 to 
132 (with 47 in our study), and the menopausal status of the 
women differ between analyses. In our study CA-125 is again 
favored by the large cohort of postmenopausal women with 
very low levels. Dividing fertile and postmenopausal women 
with early stage cancer into two groups before the analysis 
could perhaps have changed the data, especially for the pre-
menopausal group, but this was not done because of the 
small sample size. 
Currently many women are diagnosed with an ovarian cyst 
during a visit to a gynecologist or during investigation of un-
known abdominal pain by computer tomography. Women 
presenting with an ovarian cystic pelvic mass may be classi-
fied more correctly by measuring both CA-125 and HE4. We 
suggest, based on this study, that these biomarkers could be 
included in a prospective study of patients diagnosed with 
an ovarian cyst scheduled for surgery. According to their HE4 
and CA-125 levels, patients would be assigned to either a con-
servative laparoscopic ovarian cancer staging operation or an 
explorative laparotomy with debulking. 
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Standards for Different Types of Articles
Guidelines for six different types of articles have been adopted by the Journal of Gynecologic Oncology:
1. CONSORT (Consolidated Standards of Reporting Trials) standards for reporting randomized trials
2. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines for 
reporting systematic reviews and meta-analyses
3. MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines for meta-analyses 
and systematic reviews of observational studies
4. STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for 
the reporting of observational studies
5. STARD (Standards for Reporting of Diagnostic Accuracy) standards for reporting studies of diag-
nostic accuracy
6. REMARK (Reporting of Tumor Markers Studies) guidelines for reporting tumor marker prognos-
tic studies
  Investigators who are planning, conducting, or reporting randomized trials, meta-analyses of ran-
domized trials, meta-analyses of observational studies, observational studies, studies of diagnostic 
accuracy, or tumor marker prognostic studies should be familiar with these sets of standards and 
follow these guidelines in articles submitted for publication.
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